Avapritinib maintenance after stem cell transplant for AML with KIT mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking avapritinib (a targeted pill) after a stem cell transplant can help keep leukemia in remission for people whose AML has a KIT mutation. It's a maintenance therapy meant to prevent relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 years or older.
- You have had your first stem cell transplant for AML and are in complete remission.
- Your leukemia had a KIT mutation when it was first diagnosed.
- Your blood counts (white cells, platelets, hemoglobin) must be high enough before starting the study drug.
- Your major organs (liver, kidneys, heart) must be working normally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
This trial tests whether a maintenance treatment with a hypomethylating agent can help keep favorable-risk acute myeloid leukemia (AML) patients in remission after they have completed initial therapy. It is designed for patients who have achieved negative minimal residual disease (MRD) and have not received a stem cell transplant.
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.